Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Is Effective in Reducing Iron Overload in Patients with Advanced Fibrosis and Cirrhosis.
Emanuele Angelucci(Ospedale Policlinico San Martino), J. Ford(University of Pisa), C. Ressayre-Djaffer(Novartis (Switzerland)), Norbert Gattermann(Institute of Biomedical Science), Bruno Turlin(Inserm), Denis Soulières(Centre Hospitalier de l’Université de Montréal), B. Meddeb, Duran Canatan(Antalya Bilim University), Christian Rosé(Klinik und Poliklinik für Hautkrankheiten), Vincenzo De Sanctis, B. Rabault(Novartis (Switzerland)), A Mangiagli, Melody J. Cunningham
Cited by 6
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
A New Mouse Liver-specific Gene, Encoding a Protein Homologous to Human Antimicrobial Peptide Hepcidin, Is Overexpressed during Iron Overload
|Journal of Biological Chemistry|2001|1.7k
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.
|Molecular Pharmacology|1993|536
Insulin resistance–associated hepatic iron overload
|Gastroenterology|1999|509